PE HUB Second Opinion

In Second Opinion, Shire makes an unsolicited $30 billion offer to acquire Baxalta, Apple denies rumors that it’s planning on selling mobile services directly to consumers and for the third year in a row, Robert Downey Jr. is named the world’s highest paid actor.


PE HUB First Read

First Read starts your week with news that Nokia has sold its Here mapping unit to German car makers for $3 billion, India ecommerce site Snapdeal reportedly snags $500 million from Alibaba, Foxconn and SoftBank and Vice President Joe Biden is reportedly considering a 2016 presidential run.

Jill Soloway Jeffrey Tambor

peHUB First Read

First Read kicks off your week with news Anonymous hacked a jihadist website in retaliation for Charlie Hebdo attack, Netflix and Amazon score big at the Golden Globes and tech in 2015: get ready for a Jetsons world.


peHUB First Read

This morning’s First Read brings you Wall Street’s continuing turbulence, AbbVie ditches planned tax inversion and the Royals are going to the World Series.


peHUB First Read

Catch up on the midweek news as First Read has Qualcomm making a $2.5 billion dollar deal, a second health-care worker tests positive for Ebola and two tech giants offer to freeze eggs for female workers.

Shire acquires VC-backed Lumena Pharmaceuticals

Shire has acquired Lumena Pharmaceuticals. No financial terms were disclosed. Citi provided financial advice to Lumena. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders. Its backers include New Enterprise Associates, Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners.

VC-backed Genocea Biosciences hires new CFO

Genocea Biosciences said Monday that it has named Jonathan Poole as chief financial officer. Previously, Poole worked at Shire where he served as senior vice president of finance for pipeline and technical operations. Based in Cambridge, Mass., Genocea Biosciences is a developer of T-cell vaccines. Genocea’s backers include Polaris Venture Partners, Lux Ventures, Skyline Ventures, Auriga Ventures, The Bill & Melinda Gates Foundation and Morningside Ventures.

Promethera Biosciences Raises $31.4m in Series B

Belgian cell therapy company Promethera Biosciences, has raised 23.6 million euros ($31.4 million) in Series B round of investment. Among the new investors are the venture arms of Boehringer Ingelheim and Shire, Japanese investment fund Mitsui Global Investment, US company ATMI and Belgian venture capital fund Sambrinvest. PRESS RELEASE Promethera Biosciences, the Belgian cell therapy […]

NeuroPhage Raises $9M in Series B-1

NeuroPhage Pharmaceuticals Inc., a Cambridge, Mass.-based biotech company, has raised $9 million in a Series B-1 round of financing. The round was completed by existing investors, including Merieux Developpement, Shire, and undisclosed private investors. The company has raised a total of $28.6 million since its inception in 2006. PRESS RELEASE NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a […]

DBV Technologies Adds $25.5 Million in Series C

Paris-based biotech company DBV Technologies has raised 19.4 million euros ($25.5 million) in a Series C round led by new investors InnoBio Fund and Lundbeckfond Ventures. Shire plc, ALTO Invest, Sofinnova Partners and ALK Abello also contributed to the round. DBV Technologies is developing products to combat food allergies such as peanut and milk. The company’s previous investors include Apax Partners, among others.

PE HUB Community

Join the 12522 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget